Clinical Medicine and Pharmacology Clinical Medicine and Pharmacology Клиническая медицина и фармакология 2409-3750 57026 10.12737/2409-3750-2023-8-4-13-19 Обзоры reviews Обзоры The use of mycophenolate mofetil in interstitial lung diseases associated with rheumatic diseases Применение микофенолата мофетила при интерстициальных заболеваниях легких, ассоциированных с ревматическими заболеваниями Ионова Е. Д. Ionova E. D. 01 02 2023 01 02 2023 8 4 13 19 01 02 2023 https://zh-szf.ru/en/nauka/article/57026/view

Микофенолата мофетил представляет собой антиметаболит с мощным ингибирующим действием на пролиферацию Т- и В-лимфоцитов, препарат используется с начала 1990-х годов для профилактики острого отторжения трансплантата после трансплантации органов. Он также широко используется для лечения различных ревматических заболеваний с поражением легких. Интерстициальное заболевание легких – это гетерогенная группа прогрессирующих фиброзных заболеваний легких, которое часто является вторичным по отношению к ревматическому заболеванию и является частой причиной смертности. Микофенолата мофетил является основной альтернативой циклофосфамиду в качестве препарата первой линии для лечения интерстициальных заболеваний легких, связанных с ревматическими заболеваниями, или в качестве возможной поддерживающей терапии после лечения циклофосфамидом с меньшей частотой побочных эффектов. Однако применение микофенолата мофетила при интерстициальных заболеваниях легких, ассоциированных с ревматическими заболеваниями, имеет недостаточно обширные научные данные. В обзоре описаны современные сведения и достижения в области применения, эффективности и безопасности микофенолата мофетила.

Mycophenolate mofetil is an antimetabolite with a powerful inhibitory effect on the proliferation of T and B lymphocytes, the drug has been used since the early 1990s to prevent acute graft rejection after organ transplantation. It is also widely used for the treatment of various rheumatic diseases with lung damage. Interstitial lung disease is a heterogeneous group of progressive fibrotic lung diseases, which is often secondary to rheumatic disease and is a common cause of death. Mycophenolate mofetil is the main alternative to cyclophosphamide as a first-line drug for the treatment of interstitial lung diseases associated with rheumatic diseases, or as a possible maintenance therapy after treatment with cyclophosphamide with a lower frequency of side effects. However, the use of mycophenolate mofetil in interstitial lung diseases associated with rheumatic diseases has insufficient scientific data. The review describes current information and achievements in the field of application, efficacy and safety of mycophenolate mofetil.

 : заболевания соединительной ткани интерстициальная болезнь легких ревматические заболевания ревматоидный артрит системная красная волчанка системная склеродермия микофенолата мофетил азатиоприн циклофосфамид. connective tissue diseases interstitial lung disease rheumatic diseases rheumatoid arthritis systemic lupus erythematosus systemic scleroderma mycophenolate mofetil azathioprine cyclophosphamide.

Lipsky JJ. Drug profile mycophenolate mofetil. Lancet. 1996;348:1357-1359. https://doi.org/10.1016/S0140-6736(96)10310-X Lipsky JJ. Drug profile mycophenolate mofetil. Lancet. 1996;348:1357-1359. https://doi.org/10.1016/S0140-6736(96)10310-X Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2-3):85-118. https://doi.org/10.1016/S0162-3109(00)00188-0 Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2-3):85-118. https://doi.org/10.1016/S0162-3109(00)00188-0 Demedts M, Costabel U. American Thoracic Society American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Eur Respir J. 2002;19(5):794-796. https://doi.org/10.1183/09031936.02.00492002 Demedts M, Costabel U. American Thoracic Society American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Eur Respir J. 2002;19(5):794-796. https://doi.org/10.1183/09031936.02.00492002 Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34(6):429-455. https://doi.org/10.2165/00003088-199834060-00002 Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34(6):429-455. https://doi.org/10.2165/00003088-199834060-00002 FDA. CellCept® (Mycophenolate Mofetil Capsules) (Mycophenolate Mofetil Tablets) CellCept® Oral Suspension (Mycophenolate Mofetil for Oral Suspension) CellCept® Intravenous (Mycophenolate Mofetil Hydrochloride for Injection).https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050722s021,050723s019,050758s019,050759s024lbl.pdf. Accessed July 20, 2020. FDA. CellCept® (Mycophenolate Mofetil Capsules) (Mycophenolate Mofetil Tablets) CellCept® Oral Suspension (Mycophenolate Mofetil for Oral Suspension) CellCept® Intravenous (Mycophenolate Mofetil Hydrochloride for Injection).https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050722s021,050723s019,050758s019,050759s024lbl.pdf. Accessed July 20, 2020. Vernino S, Salomao DR, Habermann TM, O’Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology. 2005;65(4):639-641. tps://doi.org/10.1212/01.wnl.0000173031.56429.04. Vernino S, Salomao DR, Habermann TM, O’Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology. 2005;65(4):639-641. tps://doi.org/10.1212/01.wnl.0000173031.56429.04. Budde K, Drr M, Liefeldt L, Neumayer HH, Glander P. Enteric-coated mycophenolate sodium. Expert Opin Drug Saf. 2010;9(6): 981-994. https://doi.org/10.1517/14740338.2010.513379 Budde K, Drr M, Liefeldt L, Neumayer HH, Glander P. Enteric-coated mycophenolate sodium. Expert Opin Drug Saf. 2010;9(6): 981-994. https://doi.org/10.1517/14740338.2010.513379 Salvadori M, Bertoni E, Budde K. Superior efficacy of enteric-coated ycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis. TPS. 2010;42:1325-1328. https://doi.org/10.1016/j.transproceed.2010.03.044 Salvadori M, Bertoni E, Budde K. Superior efficacy of enteric-coated ycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis. TPS. 2010;42:1325-1328. https://doi.org/10.1016/j.transproceed.2010.03.044 Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640-646. https://doi.org/10.3899/jrheum.121043 Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640-646. https://doi.org/10.3899/jrheum.121043 Saketkoo LA, Espinoza LR. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern Med. 2008;168(15):1718-1719. https://doi.org/10.1001/archinte.168.15.1718 Saketkoo LA, Espinoza LR. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern Med. 2008;168(15):1718-1719. https://doi.org/10.1001/archinte.168.15.1718 Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009;337(5):329-335. https://doi.org/10.1097/MAJ.0b013e31818d094b Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009;337(5):329-335. https://doi.org/10.1097/MAJ.0b013e31818d094b Kelly C, Young A, Ahmad Y, et al. The effect of steroids, azathioprine and mycophenolate on the risk of death in rheumatoid arthritis. Rheumatology. 2016;55:i99-i100. https://doi.org/10.1093/rheumatology/kew144.019 Kelly C, Young A, Ahmad Y, et al. The effect of steroids, azathioprine and mycophenolate on the risk of death in rheumatoid arthritis. Rheumatology. 2016;55:i99-i100. https://doi.org/10.1093/rheumatology/kew144.019 Oldham JM, Lee C, Valenzi E, et al. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. 2016;121:P117-122. https://doi.org/10.1016/j.rmed.2016.11.007 Oldham JM, Lee C, Valenzi E, et al. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. 2016;121:P117-122. https://doi.org/10.1016/j.rmed.2016.11.007 Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130(1):30-36. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130(1):30-36. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640-646. https://doi.org/10.3899/jrheum.121043 Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640-646. https://doi.org/10.3899/jrheum.121043 Zhang G, Xu T, Zhang H, et al. [Randomized control multi-center clinical study of mycophenolate mofetil and cyclophosphamide in the treatment of connective tissue disease related interstitial lung disease]. Zhonghua Yi Xue Za Zhi. 2015;95(45):3641-3645. Zhang G, Xu T, Zhang H, et al. [Randomized control multi-center clinical study of mycophenolate mofetil and cyclophosphamide in the treatment of connective tissue disease related interstitial lung disease]. Zhonghua Yi Xue Za Zhi. 2015;95(45):3641-3645. Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009;337(5):329-335. https://doi.org/10.1097/MAJ.0b013e31818d094b Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009;337(5):329-335. https://doi.org/10.1097/MAJ.0b013e31818d094b Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640-646. https://doi.org/10.3899/jrheum.121043 Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640-646. https://doi.org/10.3899/jrheum.121043 Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol. 2010;29(10):1167-1168. https://doi.org/10.1007/s10067-010-1498-z Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol. 2010;29(10):1167-1168. https://doi.org/10.1007/s10067-010-1498-z Baqir M, Makol A, Osborn TG, Bartholmai BJ, Ryu JH. Mycophenolate mofetil for scleroderma-related interstitial lung disease: a real world experience. PLoS One. 2017;12(5):e0177107. https://doi.org/10.1371/journal.pone.0177107 Baqir M, Makol A, Osborn TG, Bartholmai BJ, Ryu JH. Mycophenolate mofetil for scleroderma-related interstitial lung disease: a real world experience. PLoS One. 2017;12(5):e0177107. https://doi.org/10.1371/journal.pone.0177107 Panopoulos ST, Bournia VK, Trakada G, Giavri I, Kostopoulos C, Sfikakis PP. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. Lung. 2013;191(5):483-489.https://doi.org/10.1007/s00408-013-9499-8 Panopoulos ST, Bournia VK, Trakada G, Giavri I, Kostopoulos C, Sfikakis PP. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. Lung. 2013;191(5):483-489.https://doi.org/10.1007/s00408-013-9499-8 Erre GL, Sebastiani M, Fenu MA, et al. Efficacy, safety, and tolerability of treatments for systemic sclerosis-related interstitial lung disease: a systematic review and network meta-analysis. J Clin Med. 2020;9(8):2560. https://doi.org/10.3390/jcm9082560 Erre GL, Sebastiani M, Fenu MA, et al. Efficacy, safety, and tolerability of treatments for systemic sclerosis-related interstitial lung disease: a systematic review and network meta-analysis. J Clin Med. 2020;9(8):2560. https://doi.org/10.3390/jcm9082560 Scleroderma Lung Study III - Combining pirfenidone with mycophenolate - Full Text View - ClinicalTrials.gov.. https://clinicaltrials.gov/ct2/show/NCT03221257. Accessed May 11, 2020 Scleroderma Lung Study III - Combining pirfenidone with mycophenolate - Full Text View - ClinicalTrials.gov.. https://clinicaltrials.gov/ct2/show/NCT03221257. Accessed May 11, 2020 Mira-Avendano IC, Parambil JG, Yadav R, et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from olymyositis/dermatomyositis. Respir Med. 2013;107(6): 890-896 Mira-Avendano IC, Parambil JG, Yadav R, et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from olymyositis/dermatomyositis. Respir Med. 2013;107(6): 890-896 Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K. Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy. Clin Rheumatol. 2019;38(2):585-590. https://doi.org/10.1007/s10067-018-4294-9 Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K. Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy. Clin Rheumatol. 2019;38(2):585-590. https://doi.org/10.1007/s10067-018-4294-9 Muangchan C, Van Vollenhoven RF, Bernatsky SR, et al. Treatment lgorithms in systemic lupus erythematosus. Arthritis Care Res. 2015;67(9):1237-1245. https://doi.org/10.1002/acr.22589 Muangchan C, Van Vollenhoven RF, Bernatsky SR, et al. Treatment lgorithms in systemic lupus erythematosus. Arthritis Care Res. 2015;67(9):1237-1245. https://doi.org/10.1002/acr.22589 Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with nclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147-157. https://doi.org/10.1016/S2213-2600(19)30341-8 Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with nclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147-157. https://doi.org/10.1016/S2213-2600(19)30341-8 Vacchi C, Sebastiani M, Cassone G, et al. Therapeutic options for the treatment of interstitial lung disease related to connective tissue diseases. a narrative review. J Clin Med. 2020;9(2):407. https://doi.org/10.3390/jcm9020407 Vacchi C, Sebastiani M, Cassone G, et al. Therapeutic options for the treatment of interstitial lung disease related to connective tissue diseases. a narrative review. J Clin Med. 2020;9(2):407. https://doi.org/10.3390/jcm9020407 Cassone G, Manfredi A, Vacchi C, et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows. J Clin Med. 2020;9(4):1082. https://doi.org/10.3390/jcm9041082 Cassone G, Manfredi A, Vacchi C, et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows. J Clin Med. 2020;9(4):1082. https://doi.org/10.3390/jcm9041082